ArticleHeart and vessels2025
Safety and efficacy of high- and very high-power short-duration ablation in overweight and obese patients with atrial fibrillation.
Article in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A New Paradigm for Atrial Fibrillation Ablation in Obesity Focusing on Substrate Remodeling and Patient-Centered Outcomes.Reviews in cardiovascular medicine · 2026Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is a common arrhythmia with increasing prevalence, especially in overweight and obese individuals. Pulmonary vein isolation (PVI) using high-power short-duration (HPSD) and very high-power short-duration (vHPSD) ablation has shown effectiveness, but data on the use of these techniques in obese and overweight patients remain limited. This study aimed to evaluate whether body mass index (BMI) influences procedural characteristics, safety, and clinical outcomes of PVI performed using HPSD and vHPSD ablation in patients with symptomatic AF. We retrospectively analyzed 367 patients (119 obese, 138 overweight, 110 normal weight) who underwent HPSD or vHPSD PVI at Ostalb-Klinikum Aalen between 2019 and 2023. Procedural parameters, complications, and 12-month AF recurrence were assessed across BMI groups. Groups were comparable except for age (normal: 68.2 ± 12, overweight: 68 ± 9.7, obese: 64 ± 10.7; p < 0.01), hypertension (54.6%, 70.3%, 73.1%; p < 0.01) and diabetes (12.7%, 11.6%, 22.7%; p = 0.03). Procedure times, fluoroscopy times, and acute PVI success rates (100%) were similar. Base impedance was significantly higher in overweight (122.8 ± 14.1) and obese (123.9 ± 17.6) than in normal weight patients (113.8 ± 21.7; p < 0.01). AF recurrence rates were similar (normal: 20%, overweight: 18.1%, obese: 20.1%; p = 0.9), with no significant BMI correlation (Spearman = - 0.02). Complications were rare (p = 0.54). HPSD and vHPSD ablation are safe and effective in overweight and obese AF patients, with comparable recurrence rates and outcomes to normal-weight patients. Higher base impedance did not impact recurrence or complications.
Indexed as
Identifiers
40423792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.